Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:27 AM
Ignite Modification Date:
2025-12-25 @ 4:27 AM
NCT ID:
NCT02582320
Eligibility Criteria:
NPP Inclusion Criteria:
1. Patients ≥18 years of age.
2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
3. A minimum of one prior line of systemic chemotherapy, chemo-immunotherapy, or an alemtuzumab-based regimen, consisting of at least two cycles of therapy.
4. Relapsed or refractory CLL with one or more of the following criteria:
* Presence of deletion of the short-arm of chromosome 17 (ie 17p deletion).
* Relapsed: Failed two or more previous treatments, at least one with a purine analogue such as fludarabine.
* Relapsed: Progression-free interval of less than 24 months from completing treatment with a nucleoside analogue, or bendamustine-containing regimen in combination with an anti-CD20 monoclonal antibody such as rituximab.
* Refractory: Failure to respond to a prior chemotherapy-based treatment, stable disease, or disease progression while on treatment.
5. Patient has active CLL requiring treatment as defined by the IWCLL 2008 criteria. A minimum of one of the following criteria is required:
* Evidence of progressive marrow failure, as manifested by the development of, or worsening of, anemia or thrombocytopenia.
* Massive (at least 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
c. Massive nodes (at least 10 cm in longest diameter), progressive, or symptomatic lymphadenopathy.
* Progressive lymphocytosis with an increase of more than 50% over a 2-month period or a lymphocyte doubling time of less than 6 months (which may be extrapolated). For patients with initial blood lymphocyte counts of less than 30 x 109/L (30,000/mL), lymphocyte doubling time should not be used as a single parameter to define indication for treatment. Factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
* Constitutional symptoms, defined as 1 or more of the following disease-related symptoms or signs:
i. Unintentional weight loss \>10% within the previous 6 months prior to screening.
ii. Significant fatigue (inability to work or perform usual activities). iii. Fever higher than 38.0°C for 2 or more weeks without evidence of infection.
iv. Night sweats for more than 1 month without evidence of infection.
6. Haematology values within the following parameters:
* Absolute neutrophil count (ANC) of ≥0.75 x109/L independent of growth factor support.
* Platelet count of ≥30 x109/L independent of platelet support.
7. Biochemical values within the following limits:
* Serum creatinine ≤2 times the upper limit of normal (ULN) or estimated glomerular filtration rate (GFR \[Crockcoft-Gault\]) ≥30 mL/minute.
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN.
* Total bilirubin ≤1.5 times ULN (unless the bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin) for whom the upper limit of serum bilirubin is 3 mg/dl.
8. No problems to swallowing regularly capsules.
9. Agreed to practice a highly effective method of birth control during and after participation in the NPP if they are of childbearing potential and sexually active.
10. Signed informed consent document (if feasible) indicating that they understand the purpose of the study, they agree to give complete access to their medical records.
NPP Exclusion criteria
1. Previous treatment with ibrutinib or participation to an ibrutinib clinical trial (ibrutinib or comparator arm).
2. Eligible to participate in a currently recruiting ibrutinib clinical trial.
3. Previously received ibrutinib as part of a clinical trial.
4. Previously received a Bruton's tyrosine kinase (BTK) inhibitor other than ibrutinib.
5. Currently enrolled in an interventional clinical trial.
6. Currently receiving chemotherapy, anticancer immunotherapy, or experimental therapy.
7. Currently recovering from acute toxicities of prior treatment for CLL.
8. Received stem cell transplantation within the past 6 months.
9. Evidence of graft-versus-host disease and/or requires immunosuppressant therapy.
10. Major surgery within the past 4 weeks or a major wound that has not fully healed.
11. History of human immunodeficiency virus (HIV) or active infection with Hepatitis C or B.
12. Ongoing uncontrolled active systemic infection.
13. Uncontrolled autoimmune haemolytic anemia (AIHA).
14. Uncontrolled idiopathic thrombocytopenic purpura (ITP).
15. Central nervous system leukemia/lymphoma or Richter's transformation.
16. Diagnosed or treated for another malignancy, other than CLL, except for:
* Malignancy treated with curative intent and with no known active disease present for ≥3 years prior to entering this named patient program and considered to be at low risk for recurrence.
* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
* Adequately treated cervical carcinoma in situ without evidence of disease.
17. Stroke within the past 6 months.
18. Intracranial haemorrhage within the past 6 months.
19. Requires anticoagulation with warfarin or equivalent vitamin K antagonist (e.g. phenprocoumon).
20. Requires treatment with a strong CYP3A inhibitor.
21. Clinically significant cardiovascular disease such as:
* Uncontrolled or symptomatic arrhythmias.
* Congestive heart failure.
* Myocardial infarction within the past 6 months.
* Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.
22. Patient has any life-threatening illness, medical condition, clinically significant.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02582320
Study Brief:
Protocol Section:
NCT02582320